Toilet seat that can detect congestive heart failure now being prepared for sale

  • As more and more cases of congestive heart failure are being diagnosed on an annual basis, a special kind of toilet seat is the newest product to help hospitals lessen their readmission rates for patients with the condition.
  • While still in the process of getting an FDA clearance, the toilet seats are devised to measure heart rate, blood pressure and other electrical and mechanical heart activities.
  • All heart data are analyzed by the use of algorithms which when presented to cardiologists, will help them determine which interventions are needed.

Yearly, about 1 million new cases of congestive heart failure are being diagnosed.

Now, a new product is making waves for aiding hospitals in monitoring patients with the condition much easier and even in their own homes.

Created by a team of researchers from the Rochester Institute of Technology, a toilet seat-based cardiovascular monitoring system aims to reduce patients with congestive heart failure, hospital readmission rates.

The revolutionary product will soon be presented by the researchers’ company Heart Health Intelligence (HHI), for clearance at the FDA, would be sold to hospitals, and issued as well to patients after discharge.

The toilet seats are designed to measure the electrical and mechanical activities of the heart. It can also monitor heart rate, blood pressure, blood oxygenation levels and the patient’s weight and stroke volume, which refers to the amount of blood pumped out of the heart per heartbeat.

The data is analyzed by algorithms; with further development, the data may serve as an alert to physicians of a deteriorating condition. Cardiologists will then determine intervention is necessary after reports are passed to them.

According to Nicholas Conn, the founder and CEO of HHI and part of the team that made the toilet seats, hospitals who readmit patients for heart failure are penalized by Medicare Centers and Medicaid Services.

“Typically, within 30 days of hospital discharge, 25 percent of patients with congestive heart failure are readmitted. After 90 days of hospital discharge, 45 percent of patients are readmitted,” Conn added.

Based on the national average for readmission rates, he further explained that the penalties to readmit 150 patients cost a yearly $500,000. If then, HHI provides patients their own monitoring toilet seats total costs will only be $200,000, which is savings more than twice the initial investment.

HHI is now targeting to work on product advancement. The company, which joined RIT’s Venture Creations earlier this year, is now working on FDA product approval as well as writing grants for additional funding, human testing and clinical studies.


Source: Science Daily

You Might Like

Leave a Reply

Your email address will not be published.